DP
RARE icon

Diadema Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Diadema Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-123,300
Closed -$3.71M – 183
2025
Q3 		$3.71M Hold
123,300
– – 0.95% 37
2025
Q2 		$4.48M Hold
123,300
– – 1.37% 25
2025
Q1 		$4.46M Buy
123,300
+17,800
+17% +$741K 1.16% 24
2024
Q4 		$4.44M Buy
+105,500
New +$5.23M 1.9% 13

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Diadema Partners's RARE Position: Q2 2026 in Review

Diadema Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 35,144 shares — an estimated $736K sold.

Diadema Partners first reported a position in RARE in Q2 2025 and held it in 3 quarters. The position peaked at $1.96M in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Diadema Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Diadema Partners sold 35,144 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $736K.
  • Diadema Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and held it in 3 quarters.
  • Diadema Partners's Ultragenyx Pharmaceutical position peaked at $1.96M in Q2 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.